A Scalawag’s Guide to Snaggin’ 6.2% Dividends in a World of Quacks and Quarters

by

There’s more than one way to skin a cat, and when it comes to the healthcare sector, folks tend to overlook the fact that not all gold lies in the apothecary’s bottle. You see, if you’re after dividend income, you’ll find the sector’s paltry 1.7% yield about as satisfying as a stale biscuit. But lo! There’s a twist to this tale, and it ain’t in the patent offices of the drugmakers.

Now, I know what you’re thinking: “Why not chase them high-yield drugmakers, eh?” Well, I’ll tell you-because they’re dancing on a tightrope with a loaded cannon for a balancing pole. But there’s a quieter path, one paved with brick and mortar, and it’s called Alexandria Real Estate (ARE). A 6.2% dividend yield, you say? That’s the kind of number that makes a man forget his own name.

What’s goin’ on with them drugmaker quacks?

Let me name names: Pfizer and Bristol Myers Squibb. Fine folks, I reckon, with yields of 6.9% and 5.2% respectively. But here’s the rub-Washington’s latest shenanigans have got these poor souls tied up in knots. You can’t trust a government that changes its mind faster than a chameleon in a kale patch. And let’s not forget the patent cliffs-those are the kind of cliffs where you leap off and find yourself in a ditch of lawsuits and expired rights.

Now, I ain’t sayin’ Alexandria is a castle in the clouds, but compared to them drugmakers, it’s a fortress built on bedrock. Why? Because while the quacks are busy chasing their tails over patent expirations, Alexandria’s got the rent comin’ in like clockwork, rain or shine.

What’s Alexandria up to, you ask?

Well, son, making drugs is a costly business. You gotta find ’em, test ’em, and then beg the government for a license to sell ’em. It’s like buildin’ a bridge with bricks and glue. But all that R&D? It don’t happen in a vacuum. No sir. It happens in buildings-tall, white buildings with labs and beakers and such. And Alexandria? They own those buildings. They’re the landlord with a heart of stone and a ledger of gold.

Bristol Myers Squibb, for instance, is their third-largest tenant. But here’s the kicker: whether them tenants discover a cure for the common cold or just a new way to make a headache, Alexandria’s rent stays steady. It’s the kind of business where the only thing that fluctuates is the weather.

Loading widget...

But now, folks are mutterin’ about Alexandria’s troubles. Occupancy rates dipped from 94.6% to 90.8% this year-a few empty chairs in the grand opera of progress. A tenant with a head full of ideas but a wallet half-empty moved on, and the company’s refocusin’ on its crown jewels. It’s a bumpy road, no doubt, but Alexandria’s still the king of the hill in the healthcare research real estate game.

And then there’s the dividend. Now, that’s a jewel worth keepin’. In Q2 2025, the FFO payout ratio was a sprightly 57%. That’s like a man who spends half his paycheck and still has a grin on his face. Office properties ain’t cheap to run, but with that kind of cushion, Alexandria’s got the luxury of sippin’ lemonade while others choke on vinegar. And let me tell you, management’s got the brass to declare they’re in the “top 10% credit rating” club. That’s Wall Street speak for “we ain’t goin’ broke anytime soon.”

Buy Alexandria while the rest of Wall Street is sellin’?

Now, I know what you’re thinkin’: “Why buy when the whole town’s sellin’?” But hear me out. Alexandria’s not just a landlord-they’re the gatekeepers of the future. The labs they rent out are where the next miracle drugs are born. And no matter how the R&D dice fall, those rent checks keep comin’. It’s the kind of business where the only thing more predictable than the rent is the sunrise.

Read More

2025-09-09 13:24